

# CANCER

## DOES THE BRAIN MATTER

A COLLABORATION BETWEEN BMI & CC

FIRST  
*from the*  
BEGINNING

CELEBRATING  
**60**  
YEARS  
OF QUALITY  
HEALTHCARE

Heart and Cancer Centre - 2011



# AKU Collaboration

*Brain and Mind Institute*



Brain and Mind Institute

*Aga Khan University*



THE AGA KHAN UNIVERSITY

*AKU Cancer Center*





“ The Heart and Cancer Centre represents a critical investment in the people of the region...Let me mention two investment areas that are most sadly short-changed in the developing world.

The first is research, and the second is education. The intimate link between quality research and quality health care is well established”

- Aga Khan, 2011



Provost AKU

**AKUN  
Cancer Center**

Center for Clinical &  
Translational Research

Multi-Disciplinary  
Clinical Service Line

AKU Medical  
College

AKU School of  
Nursing

**Cancer Center**

**Department of Hematology and Oncology**

**AKUN  
Department of  
Hematology and  
Oncology**

Clinical and Education  
Programs

Dean SOM

CEO - AKUHN

AKU Clinical  
Programs

AKU Education  
Programs

Hematology Section (3)  
Oncology Section (3)  
Radiation Therapy (3)  
Palliative Care Section (1)  
Supportive / Survivorship (1)

**Clinical Investigator Training  
Program**  
Fellowship in Hematology  
**Fellowship in Oncology**  
Radiation Therapy Resident Training

# CLINICAL TRIALS IN AFRICA

## Facts & Perspectives

Africa makes up 17% of world's population, bears 25% of the world's burden of illness

Of 2.7 million clinical trials conducted internationally, < 1% conducted in Africa

### ClinicalTrials.gov repository 2019 - of 736 clinical trials conducted in Africa

- **26 (3.5%) were cancer-related interventional trials**
- **Only 6 were conducted in countries with predominantly Black patients**
- **Trials in the African continent are predominantly conducted in S. Africa or Egypt**

Historically Time to Trial Activation > 12 months



THE AGA KHAN UNIVERSITY



# Triple Negative Breast Cancer (TNBC)

A centrally coordinated approach to determine prevalence and clinico-pathologic characteristics of high risk breast cancer in distinct ethnic regions





Contents lists available at [ScienceDirect](#)

## Translational Oncology

journal homepage: [www.elsevier.com/locate/tranon](http://www.elsevier.com/locate/tranon)




Original Research

### Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women




Mansoor Saleh<sup>a,b,c,1</sup>, Darshan Shimoga Chandrashekar<sup>d,1</sup>, Sayed Shahin<sup>e</sup>, Sumit Agarwal<sup>d</sup>, Hyung-Gyoon Kim<sup>d</sup>, Michael Behring<sup>d</sup>, Asim Jamal Shaikh<sup>e</sup>, Zahir Moloo<sup>e</sup>, Isam-Eldin A Eltoun<sup>d</sup>, Clayton Yates<sup>d,f</sup>, Sooryanarayana Varambally<sup>c,d,2</sup>, Upender Manne<sup>c,d,2,\*</sup>



Up-regulated genes

- Next Steps:**
- Identification of upregulated proteins encoded by respective mRNA
  - Further determine TNBC specificity of these protein
  - Identify potential role as diagnostic or therapeutic protein






**Figure 2**  
 The top 50 commonly down-regulated genes of the KE TNBCs, as compared to CAs and AAs, are shown in

# CRU Studies 2020-2023

Updated  
Nov 9, 2023




- Completed
- Ongoing
- Upcoming
- Pending site activation

N = x Number of subjects enrolled (enrolment closed)


N=X+: Studies currently enrolling

# A Phase Ib Study of KRAS G12C Inhibitor in Patient's Whose Tumor Carries the KRAS G12C Alteration

## Wild-Type KRAS Signaling



## Mutant KRAS<sup>G12C</sup> Signaling



MORE THAN  
**30%**  
OF ALL HUMAN CANCERS  
ARE DRIVEN BY MUTATIONS OF  
**RAS GENES**

### **KRAS G12C is an oncogenic driver mutation**

The KRAS G12C mutation occurs in about 13% of NSCLC patients, and 1%-3% of colorectal and other solid tumors. G12C is a single point mutation with a glycine-to-cysteine substitution at codon 12.<sup>1,3,4</sup> This substitution favors the activated state of KRAS, amplifying signaling pathways that lead to oncogenesis.<sup>5</sup>




mental health

**Stigma**

**IQRA**

**HOPE**




**Resilience**

**Relevance**

**CANCER**

# Cancer Neuroscience

## The Role of Sensory Neurons in the Incipient Tumor Microenvironment




Jami L. Saloman, PhD  
University of Pittsburgh



40:11

## Therapeutic Resistance and Brain Cancer Neuroscience




David Nathanson, PhD  
Molecular and Medical Pharmacology, UCLA



50:14

## Roadmap for the field of cancer neuroscience:

Lessons from nervous system development and cancer





Michelle Monje MD PhD  
Stanford University  
Howard Hughes Medical Institute



1:03:34

## Neuro-immuno-oncology as a pillar in cancer neuroscience




Asya Rolls, PhD  
Rappaport Institute for Medical Research



1:07:16

# Background




## What is Stigma?

- A social process in which individuals with certain attributes or behaviors **lose social value**
- Examples of stigmatized health conditions:
  - HIV and AIDS
  - Tuberculosis
  - Obesity
  - Mental illness
  - Substance abuse disorders
  - **BREAST CANCER**

# Overall Summary

- Breast cancer stigma items were endorsed by a majority of women, with slightly higher scores among the newly diagnosed (ns).
- Breast cancer stigma scores were significantly associated with anxiety among all patients
- Breast cancer stigma scores were significantly associated with depression
  - 13.3% of women reported major or severe depression
  - 25.0% of women experienced moderate or severe anxiety
- Financial stress and self-perceived cancer burden were highly prevalent, with significantly higher financial stress reported in newly diagnosed women.


# Resiliency can promote brain health, even in the context of stress




**Our project will investigate the biopsychosocial basis for resiliency**



# Lifetime Stress Exposures can Negatively Impact Brain Health and Accelerate Brain Aging



# Multi-Disciplinary and Multi-Level Investigation: Qualitative and Quantitative Mixed Methods Design



Medical Anthropology Core

Biomarker Core

Cancer Core

Imaging and Cognition Core


Age 45

Study Span

Age 90+

Lifespan

# Longitudinal Tracking of Patients with Newly Diagnosed Cancer to Identify Factors that Predict Resiliency versus Accelerated Aging



FOCUS ON QUALITY

# So You Want to Be a Principal Investigator

*Mansoor Saleh and Gurudatta Naik*

## What Makes A Successful Clinical Investigator

### A good clinician who demonstrates

Commitment to research

Attention to detail

Dedication to compliance

Dedication to documentation

Lead and take responsibility

### Clinical research is NOT:

A hobby to be done on the side

A mere extension of clinical work

A good clinician is NOT necessarily  
a good clinical investigator



**Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy clinicians**



P on the Go is a convenient way to participate in the CCTS Clinical Investigator Training Program, an abbreviated training curriculum for clinical investigators and trialists. The program promotes excellence in clinical practice and educates on the research capacities and expertise available to support clinical trials.

Published online 2020 Jun 12. doi: [10.1016/j.conctc.2020.100589](https://doi.org/10.1016/j.conctc.2020.100589)

PMID: [32617432](https://pubmed.ncbi.nlm.nih.gov/32617432/)

**Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy clinicians**


[Mansoor Saleh](#),<sup>a</sup> [Gurudatta Naik](#),<sup>a,\*</sup> [Penelope Jester](#),<sup>b</sup> [Cynthia Joiner](#),<sup>c</sup> [Elizabeth Westfall](#),<sup>d</sup>

[David W. Kimberlin](#),<sup>b</sup> [James Willig](#),<sup>e</sup> [David Redden](#),<sup>f</sup> [Juliette Southworth](#),<sup>b</sup> and

[Mark T. Dransfield](#)<sup>d</sup>

### AKU CC CIP PROGRESS


NUMBER OF PARTICIPANTS




■ Number of participants who completed CIP	15	14	21	24	
■ Number of Participants who attended CIP workshop	15	16	24	26	20
■ Number of applicants	15	20	27	28	66

# CITP


## Curriculum Overview



Introduction to Clinical Research and GCP



Study Investigators and Staff Roles & responsibilities



Ethical consideration in the conduct of Clinical Trials



Developing a clinical Protocol  
Budgeting for clinical Trial  
Time to Trial Activation.



The Phase of Clinical Research  
Phase I – IV Studies



Protocol writing in groups.  
Presentation of Mock Protocols and discussion



Clinical research study design  
Informed consent  
Process



Qualitative and Mixed method research Studies  
Statistical Concepts in Clinical research

+ 3 month on-line modules



THE AGA KHAN UNIVERSITY








**AKU  
BMI**



**AKU  
CC**



**Stigma**  
**DART**  
**Psychosocial-  
Oncology**  
**Brain Resilience**  
**Psilocybin in  
Palliative Care**

# A drug called HOPE - TUMAINI

